home / stock / govxw / govxw news

GOVXW News and Press, GeoVax Labs Inc. Warrants From 11/08/23

Stock Information
Company Name: GeoVax Labs Inc. Warrants
Stock Symbol: GOVXW
Market: NASDAQ
Website: geovax.com
Menu
GOVXW GOVXW Quote GOVXW Short GOVXW News GOVXW Articles GOVXW Message Board
Get GOVXW Alerts

News, Short Squeeze, Breakout and More Instantly...
GOVXW - GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Significant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin ® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck Cancer Conference showing safe administration and tumor reduction ...
GOVXW - GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced th...

GOVXW - GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Designed to Protect Immunocompromised Patients Against Severe COVID-19 ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, toda...

GOVXW - GeoVax to Participate in Upcoming November Investor and Industry Events

ATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientif...
GOVXW - GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

ATLANTA, GA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced an update on key strategic initiatives. “The third q...

GOVXW - GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Al...

GOVXW - GeoVax Receives Notice of Allowance for HIV Vaccine Patent

ATLANTA, GA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issue...
GOVXW - GeoVax to Participate in Upcoming October Investor and Industry Events

Company to Provide Updates on Phase 2 Clinical Trials for Next Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developin...

GOVXW - GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, and ProBioGen announce the signing of a landmark commercial ...

GOVXW - GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

Preclinical Data for GEO-CM02 Demonstrates Single-Dose Protection Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines ag...
Previous 10 Next 10